Lebrikizumab relieves ‘debilitating’ symptoms of hand, foot dermatitis in phase 3 study

Дата публикации: 15-10-2026 15:30:24

Lebrikizumab monotherapy improved atopic hand and foot dermatitis and the itch, pain and quality of life measures associated with it, according to data presented at the European Academy of Dermatology and Venerology Congress.Atopic hand and foot dermatitis is a common, recalcitrant and debilitating manifestation of eczema driven by an overexpression of interleukin-13, according to the late-breaking presentation. Though confined to small areas of the body, atopic hand and foot dermatitis can severely impact a patient’s quality of life, according to Patrick M. Brunner, MD, MSc, professor of

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	<![CDATA[Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial]]>	0	9.13	30-09-2026
2	Telikibart shows ‘promising efficacy’ for moderate to severe eczema	0	8.01	16-10-2026
3	Sanofi Announces Decision Not to Submit Amlitelimab in Atopic Dermatitis for Global Regulatory Reviews	0	10.91	24-07-2026
4	Quality of life improves in asthma with depemokimab	0	11.79	20-10-2026
5	New PILL for psoriasis approved... giving hope to millions suffering from debilitating skin condition	0	5.26	18-03-2026
6	FDA Approves Arcutis’ Zoryve (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2	0	19.68	29-06-2026
7	Skyrizi (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease	0	13.95	26-06-2026
8	Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes	0	22.68	12-06-2026
9	Weight loss drugs may literally be saving people's arms and legs	5	7	06-07-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 6.93. Источник: www.healio.com.